# 1. Financial Performance ## A. Key Figures * **Revenue Guidance:** **₹850–900 Cr** consolidated (current capacity) * **EBITDA Margin Target:** **20–22%** (stabilized, FY '27) ## B. Revenue Guidance * **Capacity-Led Growth:** Revenue guidance reflects full monetization of existing assets; future upside to come from **operational efficiency and integration**, not incremental capacity. * **Pharma Intermediates Delay:** **No INR200 Cr uplift** expected in FY '27 due to delayed commercial ramp-up post-validations, tempering near-term growth assumptions. ## C. EBITDA Margin * **Margin Trajectory:** EBITDA margin expansion to target band hinges on **higher plant occupancy and infrastructure utilization**, with near-term volatility from input prices. * **Technology-Driven Profitability:** New products to mirror **SDA-level gross margins** due to **near-zero waste and lower effluent costs**, signaling structural margin support. ## D. ROCE Outlook * **ROCE Rebound Ahead:** Current 7% ROCE at sub-optimal utilization is not representative; **meaningful improvement expected in FY '27** driven by higher reactor occupancy, even under stable pricing. --- # 2. Product & Segment Performance ## A. Key Figures * Pharma & Agro Intermediates Revenue: **₹471 Mn** (QoQ +45% · YoY +86%) * **Ankleshwar Plant Contribution:** **₹100–120 Cr** annual run-rate ## B. Pharma & Agro Intermediates * **Strong Commercial Momentum:** Robust sequential and annual growth driven by successful scale-up of agro intermediates, including photochlorination-based product, with full customer commitments met and **zero complaints** affirming quality. * **Capacity Expansion Underway:** Greenfield Jolva plant construction to begin this quarter, with capex focused on commercializing a new agro intermediate; current revenue excludes Jolva and new Dahej block, indicating embedded growth runway. * **Technology Differentiation:** Tatva Chintan reinforcing positioning in **complex, deep chemistries**, supporting high-barrier product development and long-term margin resilience. ## C. SDA & Catalyst Sales * **Resilient Growth Despite QoQ Dip:** SDA segment delivered strong YoY performance and 9-month revenue of ₹150 Cr, with **25–30% full-year growth expected** on new customer commercialization. * **Customer Pipeline Progress:** Two new SDA customers added, one nearing final contract stage with **commercial invoicing expected in ~4 months**, signaling near-term revenue expansion. * **Pricing Stability & Niche Positioning:** SDA prices unchanged QoQ; enduring customer relationships and unique supplier-customer dynamics in niche applications reinforce structural advantage. ## D. Electrolyte & Semiconductor * **Emerging Growth Vector:** Electrolyte salts segment showing **consistent demand improvement** and **predictable volume scaling** in energy storage and hybrid auto, now becoming a meaningful revenue contributor. * **Strategic Revenue Target:** Sales expected to rise from **1% to 7–8% of total revenue by 2026**, driven by catalytic and electrolytic chemistry expertise, signaling long-term diversification success. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Dahej Capex:** **₹100 Cr** (final expected ~₹102 Cr) * **Jolva Phase I Capex:** **₹265–270 Cr** (est.) * **SDA Capacity Utilization:** **~55%** (up from 35%) ## B. Dahej Plant Status * **Commercial Launch Imminent:** New Agrochemical plant handed over to production, with water trials ongoing and chemical trials starting February 1; commercial production set for **last week of February**. * **Profitability Catalyst:** New block resolves key bottlenecks via **solvent recovery, byproduct valorization, and improved cost efficiency**, with near-term contribution to margin expansion. * **Scalable Platform:** Existing Dahej site retains headroom for **₹850–900 Cr** in incremental revenue; newer products will remain at Dahej unless requiring Jolva’s dedicated infrastructure. ## C. Jolva Greenfield Project * **Groundbreaking Near-Term:** Site preparation advanced, with **groundbreaking in mid-February** and formal launch expected in current quarter. * **Dedicated Growth Engine:** Jolva will host **entirely new agro product lines** not feasible at Dahej due to space and infrastructure constraints; minimal operational overlap with existing site. * **Phased Execution:** First phase focuses on core infrastructure; capex allocation weighted toward **new product development** rather than expansion of current portfolio. ## D. Utilization & Efficiency * **Scale-Up Underway:** First **ton-scale production order secured** (3 batches × 3 MT) for one product, marking transition from pilot; plant modifications in progress. * **Capex Efficiency Focus:** Recent investments prioritized **utilization optimization over capacity addition**, with **~70% targeting bottleneck resolution and material reuse**. * **Available Headroom:** Current SDA utilization at **~55%** provides buffer to absorb demand growth without immediate need for further capex. --- # 4. Demand & Customer Trends ## A. Customer Commitments * **Technology Validation:** Repeat orders secured for photochlorination chemicals for April–June quarter, confirming successful deployment and customer satisfaction. * **Growth Infrastructure:** Focus on fulfilling commitments while scaling innovative chemistry capabilities to support future demand. ## B. Order Predictability * **Improved Demand Visibility:** Order patterns across key end markets have become more predictable, with healthier customer engagement levels versus prior quarters. * **Near-Term Shipment Delay:** Domestic electrolyte product shipments delayed due to logistics issues, resulting in no sales recognition this quarter. --- # 5. Growth Opportunities ## A. Key Figures * **New Intermediates Revenue (Mid-Feb Onward):** **INR250–300 Cr** expected from six new products * **New Intermediates Revenue (by CY2027):** **INR200–250 Cr** incremental, building on existing base * **Semiconductor Revenue Range (FY'28–'29):** **INR100 Cr to INR2,000 Cr** potential, dependent on adoption ## B. New Product Ramp-up * **Commercialization Accelerating:** Scale-up complete for new products; final active producer in validation, with full rollout expected in a couple of quarters. * **High-Impact Growth Vector:** New product segment starts from near-zero base, meaning incremental sales will directly boost financial performance. * **Revenue Visibility:** Six new intermediates (three pharma, three agro) to drive **INR250–300 Cr** in initial revenue, with strong momentum into CY2027. * **Product Advantage:** New offerings are **less toxic** and supported by successful trial orders validating quality at scale. ## C. Semiconductor Potential * **Milestone Reached:** First plant trial order scheduled this quarter, marking transition from R&D to early commercialization in ultra-high purity chemistry. * **Strategic Upside:** Semiconductor chemicals represent a potentially **material** new business line, though still in nascent stages. * **Optionality with High Ceiling:** Revenue outcome highly contingent on customer adoption, but full product transition could unlock **volumes beyond current capacity**. ## D. Crop Protection Focus * **Differentiated Agro Strategy:** Minimal legacy footprint enables focus on **innovative technologies** over conventional chemistry, positioning for agile market entry. * **Commercial Readiness:** New agro product with **novel technology** has passed pilot testing and received **customer-approved samples**, supporting near-term scale-up. --- # 6. Risks & Operational Challenges ## A. SDA Demand Volatility * **Manageable Geopolitical Risk:** Reciprocal tariff discussions in the U.S. remain fluid but are currently assessed as **manageable**, with no material impact on near-term business. * **Inherently Volatile Demand:** SDA revenue exhibits high variability due to campaign-based customer ordering, resulting in potential quarters with **zero sales** and unreliable quarter-on-quarter comparisons. * **Inventory & Pricing Stability:** High inventory buffers are required to meet unpredictable demand; raw material pricing for SDA has stabilized, with chemical prices showing signs of bottoming out. ## B. Technical Scalability * **Path to Profitability Improvement:** Technical constraints in the agro segment are expected to be resolved upon commissioning of a new plant, enabling scalability and **operational leverage**. * **Execution Resilience:** Strong operational discipline and internal confidence support delivery, as demonstrated by successful execution of photochlorination orders despite a **2–3 week delay**. * **Product Stability Advantage:** Zeolite order quality remains intact over prolonged storage, reinforcing long-term reliability in specialized applications. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **₹860–900 Cr** (5–3 years) * **Revenue Growth Outlook:** **20%–30%** p.a. for FY26–FY27 * **Pharma Intermediate Sales:** **₹150 Cr** expected by CY28 ## B. FY26–FY27 Growth * **Confident Growth Posture:** Company enters 2026 with improved visibility and execution momentum, underpinned by stabilizing end markets and maturing innovation. * **Demand Trajectory:** Near-term demand seen stable at 2025 levels, with **gradual recovery in agro intermediates** expected to commence in 2026. * **Upside Potential:** FY27 growth could exceed 30% if **Jolva plant achieves commercial commissioning by late CY27**. ## C. Commercialization Timeline * **Pharma Ramp-Up Underway:** Commercial supply on track for **H2 CY26**, with consolidation from **Q2 of next FY**, pending customer validation. * **Scalability Inflection:** Project remains on schedule for **full-scale commercialization by 2028**, enabling replacement of an established product and capturing significant market share.